tirzepatide mash phase 3 nash An update on in peope with metabolic liver disease #MASLD #MASH #T2D #obesity @EliLillyandCo https://t.co/cPXDLbWgCR In the SYNERGY-NASH trial, researchers – Calorie control Flavor:GLP-1 Craving Control Set Semaglutide + HRT -

tirzepatide mash phase 3 nash An update on in peope with metabolic liver disease #MASLD #MASH #T2D #obesity @EliLillyandCo https://t.co/cPXDLbWgCR In the SYNERGY-NASH trial, researchers – Calorie control Flavor:GLP-1 Craving Control Set Semaglutide + HRT -

Semaglutide + HRT - is it right for you? #menopause @drsalaswhalen

The case for plausible benefit: Many mechanisms (weight loss, blood pressure, inflammation) are not diabetes-specific Obesity-related kidney disease is common in non-diabetic CKD Cardiovascular benefits (SELECT trial) are independent of diabetes The case for uncertainty: FLOW did not enroll non-diabetic patients Hyperglycemia is a major driver in DKD that is absent in many non-diabetic CKD cases The optimal dose for non-diabetic CKD may differ from the 1.0 mg used in FLOW Dedicated trials in non-diabetic CKD are in design

Calorie control

Flavor:GLP-1 Craving Control Set

What role do diet and exercise play during a Flow Wellness program